ADAT1

Summary

ADAT1 (adenosine deaminase tRNA specific 1, HGNC:228) is a protein-coding gene on chromosome 16q23.1, encoding tRNA-specific adenosine deaminase 1 (Q9BUB4). Specifically deaminates adenosine-37 to inosine in tRNA-Ala.

This gene is a member of the ADAR (adenosine deaminase acting on RNA) family. Using site-specific adenosine modification, proteins encoded by these genes participate in the pre-mRNA editing of nuclear transcripts. The protein encoded by this gene, tRNA-specific adenosine deaminase 1, is responsible for the deamination of adenosine 37 to inosine in eukaryotic tRNA. Alternatively spliced transcript variants have been described.

Source: NCBI Gene 23536 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 112 total — 1 pathogenic
• MANE Select transcript: NM_001324445

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:228
Approved symbol	ADAT1
Name	adenosine deaminase tRNA specific 1
Location	16q23.1
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000065457
Ensembl biotype	protein_coding
OMIM	604230
Entrez	23536

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 10 protein_coding, 2 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay

ENST00000307921, ENST00000562374, ENST00000564657, ENST00000565109, ENST00000566445, ENST00000566450, ENST00000567281, ENST00000568001, ENST00000568478, ENST00000568510, ENST00000898849, ENST00000966251, ENST00000966252, ENST00000966253

RefSeq mRNA: 10 — MANE Select: NM_001324445 NM_001324444, NM_001324445, NM_001324446, NM_001324448, NM_001324449, NM_001324450, NM_001324451, NM_001324452, NM_001324453, NM_012091

CCDS: CCDS10922

Canonical transcript exons

ENST00000564657 — 10 exons

Exon	Start	End
ENSE00002601564	75622403	75623281
ENSE00003505993	75620631	75620820
ENSE00003529428	75620266	75620334
ENSE00003541224	75612243	75612861
ENSE00003543477	75608224	75608323
ENSE00003544127	75608843	75608988
ENSE00003571105	75618586	75618640
ENSE00003594337	75603085	75603171
ENSE00003624907	75617142	75617272
ENSE00003912731	75596868	75600348

Expression profiles

Bgee: expression breadth ubiquitous, 255 present calls, max score 96.67.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.6375 / max 110.7990, expressed in 1783 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
158181	8.9996	1780
158180	0.6379	366

Top tissues by expression

286 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oocyte	CL:0000023	96.67	gold quality
secondary oocyte	CL:0000655	95.37	gold quality
left testis	UBERON:0004533	92.50	gold quality
right testis	UBERON:0004534	92.48	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	91.86	gold quality
islet of Langerhans	UBERON:0000006	91.78	gold quality
gall bladder	UBERON:0002110	91.71	gold quality
rectum	UBERON:0001052	91.28	gold quality
right coronary artery	UBERON:0001625	90.83	gold quality
metanephros cortex	UBERON:0010533	90.72	gold quality
stromal cell of endometrium	CL:0002255	90.67	gold quality
lymph node	UBERON:0000029	90.62	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	90.44	gold quality
right uterine tube	UBERON:0001302	90.36	gold quality
spleen	UBERON:0002106	90.36	gold quality
testis	UBERON:0000473	90.31	gold quality
right adrenal gland	UBERON:0001233	90.31	gold quality
right adrenal gland cortex	UBERON:0035827	90.25	gold quality
left adrenal gland	UBERON:0001234	90.11	gold quality
left adrenal gland cortex	UBERON:0035825	90.04	gold quality
left lobe of thyroid gland	UBERON:0001120	89.90	gold quality
ganglionic eminence	UBERON:0004023	89.72	gold quality
ascending aorta	UBERON:0001496	89.63	gold quality
adenohypophysis	UBERON:0002196	89.62	gold quality
ectocervix	UBERON:0012249	89.55	gold quality
thoracic aorta	UBERON:0001515	89.51	gold quality
left uterine tube	UBERON:0001303	89.50	gold quality
right lobe of thyroid gland	UBERON:0001119	89.45	gold quality
adrenal tissue	UBERON:0018303	89.38	gold quality
adrenal gland	UBERON:0002369	89.35	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.73
E-MTAB-6386	no	203.68

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

100 targeting ADAT1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-12118	100.00	65.88	1270
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-6891-5P	99.98	66.53	1372
HSA-MIR-3173-3P	99.98	66.49	1217
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-570-3P	99.96	72.41	4910
HSA-MIR-4778-3P	99.93	70.40	1818
HSA-MIR-6753-3P	99.93	66.57	637
HSA-MIR-7107-3P	99.93	66.73	627
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-4493	99.90	66.48	977
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-345-3P	99.89	70.23	1421
HSA-MIR-4492	99.87	68.25	3611
HSA-MIR-5582-3P	99.86	72.48	4221
HSA-MIR-544A	99.84	68.66	1965
HSA-MIR-4659A-3P	99.80	72.62	4248
HSA-MIR-4659B-3P	99.80	72.62	4248
HSA-MIR-26A-5P	99.78	73.52	2303
HSA-MIR-26B-5P	99.78	73.51	2305
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-6794-5P	99.76	66.38	1048
HSA-MIR-3680-3P	99.75	72.51	3095
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-187-5P	99.74	70.26	1404
HSA-MIR-4465	99.71	72.56	2096
HSA-MIR-3659	99.70	67.97	694
HSA-MIR-4716-3P	99.69	66.73	1022

Cross-species orthologs

7 orthologs

Organism	Symbol	Gene ID
danio_rerio	adat1	ENSDARG00000061348
mus_musculus	Adat1	ENSMUSG00000031949
rattus_norvegicus	Adat1	ENSRNOG00000019434
drosophila_melanogaster	CG12493	FBGN0035571
drosophila_melanogaster	blanks	FBGN0035608
caenorhabditis_elegans	adr-1	WBGENE00000079
caenorhabditis_elegans	D2005.1	WBGENE00008397

Paralogs (14): STAU2 (ENSG00000040341), ZFR (ENSG00000056097), ZFR2 (ENSG00000105278), STAU1 (ENSG00000124214), ILF3 (ENSG00000129351), TARBP2 (ENSG00000139546), ADAD2 (ENSG00000140955), ILF2 (ENSG00000143621), ADAR (ENSG00000160710), ADAD1 (ENSG00000164113), STRBP (ENSG00000165209), PRKRA (ENSG00000180228), ADARB2 (ENSG00000185736), ADARB1 (ENSG00000197381)

Protein

Protein identifiers

tRNA-specific adenosine deaminase 1 — Q9BUB4 (reviewed: Q9BUB4)

Alternative names: tRNA-specific adenosine-37 deaminase

All UniProt accessions (8): Q9BUB4, A0A0G2JLA8, H3BNT8, H3BP18, H3BP27, H3BSM1, H3BU72, H3BV89

UniProt curated annotations — full annotation on UniProt →

Function. Specifically deaminates adenosine-37 to inosine in tRNA-Ala.

Tissue specificity. Ubiquitously expressed.

Cofactor. Binds 1 myo-inositol hexakisphosphate (IP6) per subunit.

Similarity. Belongs to the ADAT1 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9BUB4-1	1	yes
Q9BUB4-2	2

RefSeq proteins (10): NP_001311373, NP_001311374, NP_001311375, NP_001311377, NP_001311378, NP_001311379, NP_001311380, NP_001311381, NP_001311382, NP_036223 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002466	A_deamin	Domain

Pfam: PF02137

Enzyme classification (BRENDA):

• EC 3.5.4.34 — tRNAAla(adenine37) deaminase (BRENDA: 3 organisms, 4 substrates, 1 inhibitors, 1 Km, 1 kcat entries)

Substrate kinetics (BRENDA)

1 substrates with measured Km, best-characterized 1. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ADENINE37 IN TRNAALA	—	1

Catalyzed reactions (Rhea), 1 shown:

• adenosine(37) in tRNA(Ala) + H2O + H(+) = inosine(37) in tRNA(Ala) + NH4(+) (RHEA:50968)

UniProt features (22 total): binding site 9, sequence variant 4, sequence conflict 3, chain 1, domain 1, modified residue 1, splice variant 1, region of interest 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BUB4-F1	82.40	0.69

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 89 (proton donor)

Ligand- & substrate-binding residues (9): 305; 435; 470; 87; 93; 94; 142; 299; 302

Post-translational modifications (1): 191

Function

Pathways and Gene Ontology

Reactome pathways

3 pathways

ID	Pathway
R-HSA-6782315	tRNA modification in the nucleus and cytosol
R-HSA-72306	tRNA processing
R-HSA-8953854	Metabolism of RNA

MSigDB gene sets: 96 (showing top): ELVIDGE_HYPOXIA_DN, BUYTAERT_PHOTODYNAMIC_THERAPY_STRESS_DN, GOBP_TRNA_METABOLIC_PROCESS, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, SANSOM_APC_TARGETS_UP, TIEN_INTESTINE_PROBIOTICS_24HR_UP, NOUZOVA_TRETINOIN_AND_H4_ACETYLATION, ACEVEDO_LIVER_CANCER_UP, GOBP_TRNA_PROCESSING, REACTOME_METABOLISM_OF_RNA, SANSOM_APC_TARGETS, SANSOM_APC_TARGETS_REQUIRE_MYC, GOMF_HYDROLASE_ACTIVITY_ACTING_ON_CARBON_NITROGEN_BUT_NOT_PEPTIDE_BONDS_IN_CYCLIC_AMIDINES, ELVIDGE_HIF1A_TARGETS_UP

GO Biological Process (2): tRNA processing (GO:0008033), RNA processing (GO:0006396)

GO Molecular Function (6): RNA binding (GO:0003723), tRNA-specific adenosine deaminase activity (GO:0008251), tRNA-specific adenosine-37 deaminase activity (GO:0043829), metal ion binding (GO:0046872), adenosine deaminase activity (GO:0004000), hydrolase activity (GO:0016787)

GO Cellular Component (0):

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
tRNA processing	1
Metabolism of RNA	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA processing	1
tRNA metabolic process	1
gene expression	1
RNA biosynthetic process	1
primary metabolic process	1
nucleic acid binding	1
adenosine deaminase activity	1
catalytic activity, acting on a tRNA	1
tRNA-specific adenosine deaminase activity	1
cation binding	1
hydrolase activity, acting on carbon-nitrogen (but not peptide) bonds, in cyclic amidines	1
deaminase activity	1
catalytic activity	1

Protein interactions and networks

STRING

584 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ADAT1	ADAT3	Q96EY9	953
ADAT1	ADAT2	Q7Z6V5	931
ADAT1	KARS1	Q15046	920
ADAT1	AARS1	P49588	865
ADAT1	C9J5N1	C9J5N1	650
ADAT1	AARSD1	Q9BTE6	650
ADAT1	TRMT5	Q32P41	580
ADAT1	DUXB	A0A1W2PPF3	561
ADAT1	TERF2IP	Q9NYB0	545
ADAT1	IPPK	Q9H8X2	506
ADAT1	DUXA	A6NLW8	482
ADAT1	QPCTL	Q9NXS2	448
ADAT1	PTPA	Q15257	445
ADAT1	YARS1	P54577	435
ADAT1	PKDREJ	Q9NTG1	418
ADAT1	PLAC9	Q5JTB6	418

IntAct

2 interactions, top by confidence:

A	B	Type	Score
CFTR	ADAT1	psi-mi:“MI:0915”(physical association)	0.370

BioGRID (10): ADAT1 (Affinity Capture-RNA), ADAT1 (Affinity Capture-RNA), ADAT1 (Affinity Capture-RNA), ADAT1 (Affinity Capture-RNA), ADAT1 (Affinity Capture-RNA), QTRTD1 (Co-fractionation), ADAT1 (Affinity Capture-RNA), ADAT1 (Proximity Label-MS), ADAT1 (PCA), ADAT1 (Affinity Capture-RNA)

ESM2 similar proteins: A7UL74, B6DMK2, E7F654, F1Q7Z7, F1S5L4, F4HU58, F4KH86, F6QXW0, O09053, O42912, O94443, P53065, P97564, Q12383, Q22618, Q28FE8, Q32NG0, Q3EBC8, Q3KR54, Q3YK19, Q497V5, Q4KLT3, Q4R7N3, Q501D5, Q5D892, Q5RAY7, Q5SUE7, Q5SXJ3, Q5ZI16, Q61586, Q61J97, Q68FJ9, Q6CP50, Q6DHJ1, Q6NXH8, Q7ZVS8, Q84MA1, Q8BWQ4, Q8C1Z8, Q8IYT2

Diamond homologs: O42912, P53065, P97616, Q28FE8, Q4R7N3, Q5ZI16, Q9BUB4, Q9JHI2, Q9JI20, Q9NS39, Q96M93, Q9U3D6, Q9V3R6, Q3KR54, Q5SUE7, P51400, P78563, Q22618, Q91ZS8, Q9NII1

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

112 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	93
Likely benign	6
Benign	0

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1682045	NC_000016.9:g.(?75428968)(75690509_?)del	Pathogenic

SpliceAI

1718 predictions. Top by Δscore:

Variant	Effect	Δscore
16:75608324:C:CC	acceptor_gain	1.0000
16:75608326:A:C	acceptor_gain	1.0000
16:75612270:T:TA	donor_gain	1.0000
16:75620260:GCTT:G	donor_loss	1.0000
16:75620261:CTTA:C	donor_loss	1.0000
16:75620262:TTAC:T	donor_loss	1.0000
16:75620263:TACCG:T	donor_loss	1.0000
16:75620264:A:AC	donor_gain	1.0000
16:75620264:ACC:A	donor_loss	1.0000
16:75620265:C:CA	donor_loss	1.0000
16:75620265:C:CC	donor_gain	1.0000
16:75620265:CCGTT:C	donor_gain	1.0000
16:75620272:T:TA	donor_gain	1.0000
16:75620330:TGTCA:T	acceptor_gain	1.0000
16:75620331:GTCA:G	acceptor_gain	1.0000
16:75620332:TCA:T	acceptor_gain	1.0000
16:75620333:CA:C	acceptor_gain	1.0000
16:75620333:CAC:C	acceptor_gain	1.0000
16:75620333:CACTG:C	acceptor_loss	1.0000
16:75620335:C:CC	acceptor_gain	1.0000
16:75620335:CTGTG:C	acceptor_loss	1.0000
16:75620336:T:A	acceptor_loss	1.0000
16:75620627:TCA:T	donor_loss	1.0000
16:75620628:CA:C	donor_loss	1.0000
16:75620629:A:AC	donor_gain	1.0000
16:75620630:C:CC	donor_gain	1.0000
16:75620630:C:CT	donor_loss	1.0000
16:75620630:CCTT:C	donor_gain	1.0000
16:75620631:CTTG:C	donor_gain	1.0000
16:75620632:TTGC:T	donor_gain	1.0000

AlphaMissense

709 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:75618621:G:C	S86R	0.990
16:75618621:G:T	S86R	0.990
16:75618623:T:G	S86R	0.990
16:75618594:A:C	S95R	0.988
16:75618594:A:T	S95R	0.988
16:75618596:T:G	S95R	0.988
16:75618604:G:T	A92D	0.988
16:75618625:T:G	D85A	0.988
16:75618625:T:A	D85V	0.986
16:75620697:C:G	A35P	0.986
16:75620694:C:G	A36P	0.985
16:75618597:C:A	R94S	0.984
16:75618597:C:G	R94S	0.984
16:75618624:A:C	D85E	0.984
16:75618624:A:T	D85E	0.984
16:75618626:C:G	D85H	0.984
16:75617267:A:G	L100P	0.981
16:75620709:A:G	W31R	0.981
16:75620709:A:T	W31R	0.981
16:75618616:G:T	A88D	0.977
16:75620311:C:G	G65R	0.977
16:75620311:C:T	G65R	0.977
16:75618625:T:C	D85G	0.976
16:75620777:G:T	A8D	0.976
16:75618598:C:G	R94T	0.975
16:75620296:A:G	C70R	0.975
16:75620310:C:T	G65E	0.975
16:75620317:A:G	S63P	0.975
16:75618618:A:C	H87Q	0.974
16:75618618:A:T	H87Q	0.974

dbSNP variants (sampled 300 via entrez): RS1000019493 (16:75603580 T>C), RS1000052965 (16:75598249 G>C), RS1000085113 (16:75598419 C>T), RS1000112630 (16:75613488 G>C), RS1000145714 (16:75616952 A>G), RS1000155554 (16:75617273 C>A,T), RS1000241629 (16:75623452 G>A,C), RS1000288673 (16:75619198 G>A,C), RS1000322332 (16:75619483 G>T), RS1000478612 (16:75622308 T>C), RS1000574929 (16:75607418 C>T), RS1000621672 (16:75602365 A>G), RS1000681045 (16:75609564 C>A), RS1000760598 (16:75604236 C>A), RS1000841682 (16:75598907 T>C)

Disease associations

OMIM: gene MIM:604230 | disease phenotypes: MIM:614970, MIM:615397

GenCC curated gene-disease

Mondo (3): prostate cancer (MONDO:0008315), Joubert syndrome 20 (MONDO:0013994), Meckel syndrome, type 11 (MONDO:0014164)

Orphanet (3): Familial prostate cancer (Orphanet:1331), Isolated Joubert syndrome (Orphanet:475), Meckel syndrome (Orphanet:564)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST002553_10	Pancreatic cancer	1.000000e-10

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

24 total (human), top 24 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
aristolochic acid I	decreases expression	1
GSK-J4	decreases expression	1
bisphenol A	decreases methylation	1
cobaltous chloride	decreases expression	1
butyraldehyde	decreases expression	1
potassium chromate(VI)	affects cotreatment, decreases expression	1
2,3-bis(3’-hydroxybenzyl)butyrolactone	affects cotreatment, increases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
ICG 001	increases expression	1
abrine	decreases expression	1
Resveratrol	affects cotreatment, increases expression	1
Acetaminophen	increases expression	1
Ethanol	decreases expression	1
Caffeine	increases phosphorylation	1
Coumestrol	affects cotreatment, increases expression	1
Doxorubicin	decreases expression	1
Estradiol	increases expression	1
Plant Extracts	affects cotreatment, increases expression	1
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	1
Cyclosporine	decreases expression	1
Cadmium Chloride	decreases expression	1
Lactic Acid	decreases expression	1
tert-Butylhydroperoxide	decreases expression	1

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer